biostudies-literatureDy GKNCI NIH HHS3311-3317https://www.ebi.ac.uk/biostudies/studies/S-EPMC10414711biostudies-literatureUnknown41(18)<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>In the longest follow-up, to our knowledge, for a KRAS^G12C inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883). This multicenter, single-group, open-labeJournal of clinical oncology : official journal of the American Society of Clinical OncologyLong-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.PMC10414711R01 CA230745P30 CA008748P30 CA138292P01 CA129243R01 CA279264R01 CA230267Sacher AGHindoyan AAddeo ALito PAnderson ADesai JHong DSTomasini PLi BTDooms CItaliano ASnyder WKim DWTakahashi TRamalingam SSGovindan RTran QSkoulidis FFalchook GSWolf JDy GKSchuler MJones SVelcheti VfalseLong-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>In the longest follow-up, to our knowledge, for a KRAS^G12C inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883). This multicenter, single-group, open-labe2023-01-01T00:00:00Z2023 Jun2025-05-29T19:15:29.769Z2024-11-05T19:25:05.85ZS-EPMC104147113709823210.1200/JCO.22.02524